Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results, Beats Expectations By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS) released its earnings results on Thursday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.20 million.

Arbutus Biopharma Stock Up 5.0 %

Arbutus Biopharma stock traded up $0.17 during trading hours on Friday, hitting $3.44. 474,998 shares of the company traded hands, compared to its average volume of 1,032,135. The firm’s 50-day simple moving average is $3.33 and its two-hundred day simple moving average is $3.58. The firm has a market cap of $650.91 million, a P/E ratio of -7.99 and a beta of 1.93. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.73.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Friday. StockNews.com downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.